Proud For Profits
  • Investing
  • Stock
  • Latest News
  • Economy
  • Investing
  • Stock
  • Latest News
  • Economy
No Result
View All Result
Proud For Profits
No Result
View All Result
Home Stock

Castle Biosciences stock falls following Medicare coverage denial

by
January 10, 2025
in Stock
0
Castle Biosciences stock falls following Medicare coverage denial

Investing.com — Shares of Castle Biosciences (NASDAQ:CSTL) tumbled 9% after Novitas, a regional Medicare contractor, finalized its decision not to cover one of the company’s cancer tests. The Novitas Medicare Administrative Contractor (MAC) confirmed a local coverage determination (LCD) that resulted in the non-coverage of Castle’s DecisionDx-SCC test. This decision is set to take effect on February 23.

The recent development follows a precedent set by a similar non-coverage decision made by MolDx last year. Despite the setback, analysts have indicated that this outcome was anticipated. Leerink Partners’ Puneet Souda maintained an outperform rating, albeit lowering the price target to $45 from $50, stating, “the non-coverage decision was somewhat expected following a similar decision by MolDx last year.” Souda also mentioned that Castle Biosciences is expected to receive payment for the test until February 23, with no further impact on the company’s DDx-SCC revenue in 2025 and beyond. The analyst believes that with the controversy now settled, Castle presents “a slightly cleaner story ahead with 2 key products.”

Echoing this sentiment, Canaccord Genuity’s Kyle Mikson reiterated a buy rating with a price target of $42. Mikson’s commentary highlighted that the final LCD decision was anticipated by investors and the market had already discounted the DDx-SCC revenue beyond 2024 from their models. “This outcome has been expected by investors,” Mikson stated, suggesting that the resolution of the issue removes an overhang and provides clarity on Castle’s future, despite acknowledging that it may take years to achieve coverage. With the company’s strong fundamentals and discounted valuation, Mikson views Castle Biosciences shares as highly attractive.

The non-coverage decision is a significant event for Castle Biosciences, impacting the company’s financial outlook. However, the market had already factored in the potential for such an outcome, and the focus now shifts to how the company will navigate its path forward without the Medicare coverage for its DDx-SCC test.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com
Previous Post

Pfizer must face lawsuit over diversity fellowship program, US court rules

Next Post

Ex-McKinsey partner pleads guilty to destroying records about work promoting opioids

Next Post
Ex-McKinsey partner pleads guilty to destroying records about work promoting opioids

Ex-McKinsey partner pleads guilty to destroying records about work promoting opioids

Enter Your Information Below To Receive Trading Ideas and Latest News

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    Popular News

    How technology has changed inauguration coverage

    How technology has changed inauguration coverage

    January 20, 2025
    AOC launches series of explosive Instagram rants on eve of inauguration: ‘I don’t celebrate rapists’

    AOC launches series of explosive Instagram rants on eve of inauguration: ‘I don’t celebrate rapists’

    January 20, 2025
    Here’s How To Find The Best Upcoming Earnings Reports

    Here’s How To Find The Best Upcoming Earnings Reports

    January 20, 2025
    Track all markets on TradingView

    About Proud For Profits

    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Main Categories

    • Investing
    • Stock
    • Latest News
    • Economy

    Latest News

    • How technology has changed inauguration coverage
    • AOC launches series of explosive Instagram rants on eve of inauguration: ‘I don’t celebrate rapists’
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 proudforprofits.com | All Rights Reserved

    No Result
    View All Result
    • Investing
    • Stock
    • Latest News
    • Economy

    Copyright © 2025 proudforprofits.com | All Rights Reserved